Company signals
Incyte
2 signals in the current window, with MitchelLake's leadership read on each.
Market context: the MitchelLake Talent Market Index reads 108.5 — Hot; EMEA signal share is steady (-1.2pts).
Signals at Incyte
Strategic Hiring
EMEAIncyte making a $2 billion blood disease bet, signaling major strategic commitment to hematology pipeline expansion
Leadership read: Will likely need senior research scientists, clinical development leads, hematology specialists, and commercial/market access leaders to support the significant investment in blood disease treatments
curated · 2026-06-08 · context →
Ma Activity
EMEAIncyte acquiring Vega Therapeutics (Star Therapeutics' subsidiary) for $1.25B upfront plus up to $750M in milestone payments. Vega has Phase 3 bleeding disorder candidate.
Leadership read: Will need clinical development leads, regulatory affairs specialists, integration managers, and commercial launch team for bleeding disorder indication. R&D talent to advance Phase 3 program.
primary · 2026-06-08 · context →